default author photo

Burcu Aslan

University of Texas at Houston - MD Anderson Cancer Center

1901 East Road, Unit 1950

Unit 1905

Houston, TX 77030

United States

SCHOLARLY PAPERS

2

DOWNLOADS

147

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

PTGER3 Induces Ovary Tumorigenesis and Confers Resistance to Cisplatin Therapy Through Up-Regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 Axis

, EBioMedicine, 40, 290-304. https://doi.org/10.1016/j.ebiom.2018.11.045
Number of pages: 1 Posted: 22 Dec 2018
University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, Houston Methodist Research Institute - Department of Nanomedicine, University of Texas at Houston - Department of Experimental Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, Centro de Investigación y de Estudios Avanzados del IPN (CINVESTAV-IPN), Houston Methodist Research Institute - Department of Nanomedicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Experimental Therapeutics, Houston Methodist Research Institute - Department of Nanomedicine, AM Biotechnologies LLC, University of Texas at Houston - Department of Gynecologic Oncology and University of Texas at Houston - Department of Experimental Therapeutics
Downloads 103 (674,591)

Abstract:

Loading...

PTGER3, ovarian cancer, RNA interference, chemically modified siRNA, cisplatin resistance, ETS1, ELK1, CFTR

2.

Exosomal Mirna Confers Chemo Resistance Via Targeting Cav1/p-gp/M2-Type Macrophage Axis in Ovarian Cancer

, EBioMedicine, Volume 38, December 2018, Pages 100-112, https://doi.org/10.1016/j.ebiom.2018.11.004
Number of pages: 45 Posted: 20 Sep 2018
University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, Rutgers University, New Brunswick, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, Hacettepe University, Rutgers University, New Brunswick, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and University of Texas at Houston - Department of Experimental Therapeutics
Downloads 44 (1,133,231)

Abstract:

Loading...

exosome, oncomiR, miR-1246, ovarian cancer, Cav1, chemoresistance